Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis

Phase 2 Terminated 6 enrolled Gustave Roussy, Cancer Campus, Grand Paris

RandomizedParallel-groupSingle-blindTreatment

Summary

To assess the efficacy of pasireotide in the reduction of clinically relevant postoperative digestive leakage after CRS plus HIPEC compared to placebo

Timeline

Start: 2020-09-03
Primary completion: 2024-02-07
Completion: 2024-02-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pasireotide	Other / unclassified	0.9 mg	Subcutaneous

Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis

Summary

Timeline

Drugs

Indications